Globally, one in four people will be affected by psychiatric or neurological disorders during their lifetime.1 With an estimated affected population of 450 million people, mental disorders are among the leading causes of ill-health and disability worldwide.1 At the recent Lundbeck Neuroscience Symposium held at Hilton Kota Kinabalu from 3–5 November 2017, three renowned key opinion leaders from the field of psychiatry shared their insights into the optimal management of bipolar disorder and schizophrenia.
At a recent Lundbeck Neuroscience Symposium at Hilton Kota Kinabalu, Professor Bernhard Baune discussed important clinical considerations in the management of behavioural and psychological symptoms of dementia (BPSD), focussing on the role of memantine hydrochloride (Ebixa®; Lundbeck).
In this issue of MIMS PsychiatrySupplement, we bring you clinical updates related to managing depression and optimizing functional recovery in patients with depression, as well as a symposium highlight of the Lundbeck Malaysia Neuroscience Symposium.
On 6 November 2016, in conjunction with the first year anniversary of vortioxetine (Brintellix®, Lundbeck) in Malaysia, two distinguished speakers, Professor Gin S Malhi and Dr Pranab Kalita shared updates on depression and the use of vortioxetine in order to help patients with major depressive disorders (MDD) to return to their premorbid functional states. The session was followed by three case presentations.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Psychiatry - Malaysia digital copy today!
First-recorded diagnoses of psychiatric disorders are associated with increases in risk of subsequent self-harm that vary by diagnostic categories across gender and age groups, with the highest risk observed in patients with substance misuse or dependence, a 10-year case-control study in Hong Kong has shown.